Bedamustine
Phase 3Small molecule
Bedamustine is one of 7 small molecule programs targeting Brentuximab Vedotin. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Brentuximab Vedotin
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Beyfortus
BeiGenePhase 3
DTIC-Dome
BayerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Vepesid
AAvyxa
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Bedamustine
CChildren's Cancer Group, China
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bedamustine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CChildren's Cancer Group, China